

Experimental Models of Thrombocytopenia in Laboratory Animals and their Application in Identifying the Complications of Chemotherapy Drugs

H. Kamali (MSc)¹, M.R. Khazaie (PhD)¹, E. Shobeyri (MD)², M. khazaie (PhD)^{1*}

1. Infertility and Reproductive Research Center, Kermanshah University of Medical Sciences, Kermanshah, I.R.Iran.

2. Department of Radiology and Radiotherapy, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, I.R.Iran

J Babol Univ Med Sci; 20(4); Apr 2018; PP: 48-58

Received: Sep 10th 2017, Revised: Dec 17th 2017, Accepted: Dec 24th 2017

ABSTRACT

BACKGROUND AND OBJECTIVE: Thrombocytopenia is one of the complications of chemotherapy drugs that may cause death. Different animal models of thrombocytopenia are used for clinical research and identification of its causes, each with advantages and disadvantages. The aim of this review article is to investigate the methods of thrombocytopenia induction in laboratory animals and their advantages and disadvantages.

METHODS: This systematic review was conducted using the keywords “thrombocytopenia platelet”, “chemotherapy”, “animal model”, in PubMed, Science Direct and Scopus databases from 1990 until October 2017. The title and abstract of several articles were reviewed, and after excluding the unrelated items, final articles were selected and reviewed.

FINDINGS: Animal models of thrombocytopenia are of two types of immune and non-immune. Non-immune models reduce platelet production through bone marrow suppression. Antiplatelet antibodies are used in immune models. The immune and non-immune thrombocytopenic models have some advantages and limitations and are selected according to the current therapeutic goals. Mice and rats are commonly used as laboratory animals, and cyclophosphamide and carboplatin are the most commonly used drugs.

CONCLUSION: According to the results of this study, due to the limitations of human subject research in diseases that lead to thrombocytopenia, there is a need to develop appropriate animal models for studying and identifying the factors affecting thrombocytopenia.

KEY WORDS: *Thrombocytopenia, Platelet, Chemotherapy, Animal Models.*

Please cite this article as follows:

Kamali H, Khazaie MR, Shobeyri E, Khazaie M. Experimental Models of Thrombocytopenia in Laboratory Animals and their Application in Identifying the Complications of Chemotherapy Drugs. J Babol Univ Med Sci. 2018;20(4):48-58.

*Corresponding Author; M. khazaie(PhD)

Address: Infertility and Reproductive Research Center, Kermanshah University of Medical Sciences, Faculty of Medicine, University St, Kermanshah, I.R.Iran.

Tel: +98 83 34274618

E-mail: Mkhazaei1345@yahoo.com

Introduction

Thrombocytopenia is a blood disorder that reduces platelet count to less than 100,000 per microliter and is classified into three types of mild, moderate and severe, and is observed in both acute and chronic forms (1, 2). Its clinical manifestations are purpura, bleeding from the nose, gum and digestive system and hematuria (3). The mechanism of thrombocytopenia is to reduce platelet production (with bone marrow suppression) or to increase platelet degradation due to immune system disorders (4). The primary treatment of this disease is corticosteroid, which often relapses and is reversible. The use of intravenous IGs also causes a transient increase in the number of platelets, but requires repeated administration (5).

Study and research on human thrombocytopenia is associated with ethical constraints and several issues. In addition, the in vitro models of cell culture are few and lack efficiency. For this reason, there is a special interest in the animal model of thrombocytopenia, which is generally divided into two types, namely immune and non-immune. In immune models, antiplatelet antibodies can degrade and reduce platelets. Non-immune models are produced by bone marrow suppression agents (6 – 7) (Fig. 1). There are several empirical models for the development of thrombocytopenia and identification of its effective factors, each with some advantages and disadvantages, but so far no comprehensive study has been conducted on them. Therefore, this review article was conducted to investigate the methods of inducing of thrombocytopenia in laboratory animals and to introduce the advantages and disadvantages as well as applications of these models.

Methods

This review article was conducted using the keywords “thrombocytopenia”, “platelet”, “chemotherapy”, and “animal model”, in PubMed, Science Direct and Scopus databases from 1990 until October 2017. The title and abstract of several articles were reviewed, and after excluding the unrelated items, final articles were selected and evaluated..

Results

Non-immune thrombocytopenia models: These include the use of drugs that suppress bone marrow to

reduce platelet production (Fig. 1). The use of chemotherapy drugs is associated with reduced production of blood cells. Bone marrow is the tissue that restricts the dose of these drugs, and the suppression of hematopoiesis reduces leukocytes and platelets. However, severity, period and cellular pattern of bone marrow suppression differ in different types of alkylating agents (8). In this study, the main drugs used in animal models of thrombocytopenia are examined. All of these drugs are widely used in chemotherapy for cancer patients, and their side effects include thrombocytopenia (Table 1) (9 – 39).

Cyclophosphamide: Cyclophosphamide was introduced as an antitumor agent in the treatment of cancer. Subcutaneous (SC) injection of the three doses of 100, 120 and 140 mg/kg of this drug to mice reduced the platelet count by 7% on day seven by 30%, 18% and 21%, respectively. In addition, in two other models in one group (A), tail vein injection of 200 mg/kg as the initial dose and 30 mg/kg as the maintenance dose were administered intraperitoneally (IP) in the next six days. The other group (B) received a dose of 150 mg/kg (SC) for three consecutive days. The mice in group A started to die from day 6, but no death was observed in group B. The platelet count in group A on days 7 and 15 was 59% and 74%, respectively, while in group B, they fell to 33% and 75%, respectively, on days 7 and 11. This model is suitable for pharmacodynamic testing of drugs that are designed to increase platelet count (9).

The lowest dose of cyclophosphamide was 15 mg/kg, which was administered intraperitoneally for 10 days (10). In other studies, 50 mg/kg and 100 mg/kg cyclophosphamide were used (SC) in rats (11, 12) for three days and 30 mg/kg (IP) for three days (13). In addition, 200 mg/kg dose was administered to mice through tail vein injection to induce thrombocytopenia through intravenous injection and seven days later, 30 mg/kg was injected as maintenance dose (IP). The thrombocytopenia was very intense in this model, and the mice started to die from day 6 and on day 15, death rate reached 60% (14).

Comparing doses of 25, 50, 100 and 150 mg/kg (SC) and once daily for three consecutive days, platelet count decreased significantly in all groups receiving cyclophosphamide on day 7. However, all rats receiving doses of 150 and 100 mg/kg died on days 7 and 8. Therefore, all doses caused thrombocytopenia, but 25 mg/kg was more effective and less toxic (15). Different methods for the induction of thrombocytopenia

with cyclophosphamide are presented in Table 1. In our experimental study, administration of 100 mg/kg cyclophosphamide (IP) into rats within three consecutive days resulted in the death of animals from the seventh day. Doses of 50, 70 and 80 mg/kg were also injected (IP) for three consecutive days, indicating insignificant thrombocytopenia in tested animals. Therefore, after examining different doses, 100 mg/kg dose was injected to induce thrombocytopenia, and then in the next two days, a maintenance dose of 50 mg/kg was injected. In addition to observing successful thrombocytopenia from the seventh day, animal deaths were also prevented.

Carboplatin: Carboplatin is a chemotherapy drug used to induce thrombocytopenia in animal models. Doses of 200 mg/kg (close to the dose of patients) (16) and 125 mg/kg (17, 18) were administered through tail vein injection in the studies. A study investigated the effects of carboplatin along with radiotherapy on the induction of thrombocytopenia compared with cisplatin was studied and 8 mg/kg cisplatin was administered as single dose (IP) in the first group and the other group was exposed to radiotherapy (at 3 Gy/fraction). Another group was exposed to radiotherapy (at 5 Gy/fraction) after IP injection of single dose carboplatin (1.2 mg/kg) (19). In another study on dogs, carboplatin (175 mg/m²) and doxorubicin (15 mg/m²) were used, and grade one thrombocytopenia was induced. The pharmacokinetics of carboplatin is similar to humans in dogs and is therefore a suitable model for determining dosages and therapeutic programs (20).

In another model, carboplatin was injected into mice (IP) for two consecutive days at a dose of 50 mg/kg, which reduced platelets, RBC and WBC (21). In addition, after intravenous injection (IVI) of this drug (60 mg/kg) into rats on days 9 – 11, platelet count decreased to 90% (22). McElroy et al. examined the effects of Romiplostim on mice undergoing two or three CRT (chemoradiotherapy) cycles. In the first cycle, IP injection of carboplatin (62.5 mg/kg) was done and radiotherapy (at 5 Gy/fraction) was performed four hours later. In the 2nd and 3rd cycles, 56.25 mg/kg carboplatin and radiotherapy (at 4.5 Gy/fraction) were used (23). In another model, significant thrombocytopenia was induced in cat after intravenous injection of 150, 200 and 250 mg/m² carboplatin (24) (Table 1).

Cisplatin: Cisplatin IP injection (5 and 7.5 mg/kg) was done to induce thrombocytopenia and anemia in

mice (25). In a study, 5 mg/kg of this drug (IP) was injected for five consecutive days, which significantly reduced platelet count (26). Intravenous injection of cisplatin (20 mg/m²) was administered once a week for five weeks in dogs and then, radiotherapy (at 4 Gy/fraction) was done. The dogs also underwent radiotherapy (at 2 Gy/fraction) four days a week, which eventually led to a significant reduction in leukocyte, neutrophil and platelets (27). In a study on dogs, cisplatin (60 mg/m²) (IVI), and oral administration of Firocoxib (5 mg/kg) alone or with cisplatin resulted in bone marrow suppression in 60% of dogs receiving cisplatin and 40% of the dogs receiving both medications (28).

Busulfan: Injection (SC) of busulfan (25 mg/kg) did not produce a clear thrombocytopenia in rabbits on days 0 and 3 until the 6th day. However, platelet count dropped rapidly from the second week (29). The dose of 15 mg/kg of this drug was administered to rabbits (SC) on days 0, 2, 4 and 6 (30). Busulfan was also injected (IP) to rats on days 0 and 3 at a dose of 20 mg/kg. The platelet count decreased ten days after the injection of Busulfan. The RBC and WBC count also began to decrease one day after injection (31). In another model, mice received 15 mg/kg (SC) on days 0 and 3 and thrombocytopenia was observed in mice in days 15 to 18 (32). Busulfan was used in mice (IP) at a dose of 15 mg/kg in days 0 and 3 and 20 mg/kg in days 1, 2 and 4 (33).

Bortezomib: Bortezomib is an anti-cancer drug. Tail vein injection of 2.5 mg/kg Bortezomib into mice reduced platelet count significantly on days 2 to 4 and started to improve on day 6 (34). In another model, Bortezomib (1 mg/kg) and Romidepsin (2 mg/kg) were used alone or in combined form. The mice receiving Romidepsin or a combination of the two drugs showed a decrease in WBC (50%) on day 2 and started to improve on day 4, but the group receiving the combination of Bortezomib and Romidepsin showed a more obvious thrombocytopenic effect (35).

Hydroxyurea: Gammulle et al. used Hydroxyurea in inducing thrombocytopenia in rats for the first time. Thrombocytopenia was observed 24 hours after oral administration (15 mg/kg). This drug has a high toxicity, and a low dose and one-tenth of the dose used in patients was used in this study (36).

Anagrelide: Anagrelide is used to treat chronic myeloid leukemia and thrombocytosis, and it leads to thrombocytopenia by inhibiting the puberty of megakaryocytes. The IP injection of this drug (100

µg/day) after 24 to 48 hours leads to significant thrombocytopenia (40% normal count) (37). In another model, oral administration of this drug (0.083 mg/kg) for 15 days induced thrombocytopenia (38).

Oxaliplatin: Oxaliplatin is an anticancer drug that was injected intraperitoneally in rats at a dose of 0.8 mg/kg twice a week for 8 weeks, and induced significant thrombocytopenia eight days after the last injection. The weight of the spleen was significantly higher, indicating that the mechanism of platelet reduction in this model was associated with platelet aggregation in the spleen (39).

Immune thrombocytopenia

Passive antibody transfer model of immune thrombocytopenia: Almost all animal models of immune thrombocytopenia are passive, in which serum injections or antiplatelet monoclonal antibodies induce thrombocytopenia. Various animals including mice, rats, rabbits and dogs have been used in these models (40, 41) (Fig. 1). Corash et al. induced thrombocytopenia by transferring the antiplatelet serum to the C57BL/6 and CH3 mice (42). Cox et al. also observed that the injection of rabbit IgG of antiplatelet serum led to the induction of severe thrombocytopenia in Balb/c and C57BL/6 mice (43). Lecut et al. also reduced platelet in Balb/c mice by injecting antiplatelet antibodies prepared from guinea pig serum (44).

Over the past three decades, monoclonal antibodies were used against platelets of different animals. One of the first cases was the monoclonal antibody (4A5) of rats that was used to induce thrombocytopenia in mice (45). Hamster's 1C2 antibody was also used against mice and rat platelets (46). RPM.9 antibody was also used to induce thrombocytopenia in rats (47). Advantage of 1C2 and 4A5 monoclonal antibodies is the reaction with platelet and megakaryocyte.

Adoptive cell transfer of immune thrombocytopenia: Adaptive immune thrombocytopenia is a kind of passive immunity that is caused by the transfer of immunological agents, such as splenocyte (from the white blood cells of the spleen) to the host's body and creating an immune response. In the primary models, splenocyte was transmitted from patients with chronic thrombocytopenia to BALB/c mice exposed to lethal radiation. Antiplatelet antibodies were observed in mice after 2 – 8 weeks, but did not result in thrombocytopenia (48). BALB/c CD61 knockout mice were immunized through wild-type platelets and their splenocytes were transferred to the mice with SCID

(severe combined immunodeficiency) for induction of antibody-dependent thrombocytopenia. In a study, splenocytes of mice after developing thrombocytopenia through wild-type platelets were transferred to SCID mice, and the antibody-induced thrombocytopenia was resistant to platelet injection (49). Apart from SCID mice, which received splenocyte without cell depletion, depletion of T cells (CD4 +) from splenocytes reduced their ability to produce thrombocytopenia or the production of antiplatelet antibodies, but the release of splenocytes from T cells (CD8 +) does not influence their ability to produce thrombocytopenia (50).

Secondary immune thrombocytopenia: Platelet reduction may be primary or may occur due to antibodies that lead to platelet destruction. Secondary immune thrombocytopenia occurs in conditions such as chronic and acute infections and certain medications, leading to the production of antibody against platelet.

Drug – induced immune thrombocytopenia (DITP): This immune thrombocytopenia model examines the role of certain drugs in the production of this type of thrombocytopenia. In a study, the effect of phenobarbital on thrombocytopenia in dogs was investigated (51). In another study, thrombocytopenia, leukopenia, and anemia were induced using phenobarbital in dogs (52). Another drug that leads to immune thrombocytopenia is heparin. In the study of Reilly et al., spleen tyrosine kinase (Syk) prevented heparin-induced thrombocytopenia in transgenic mice (53). The induction of an animal model of heparin – induced thrombocytopenia is difficult due to the lack of FcγRIIA receptors in mice platelets. In addition, the platelets of the mice do not express the human PF4 platelet factor (54). Thus, transgenic mice that express both human FcγRIIA and PF4 were used here. In this case, the monoclonal antibody of knockout mice (KKO) reacted against the PF4/heparin complex and reduced the platelet count by 80% (55). This model can be used as a systematic study to identify important factors in the development of HIT and to explore possible therapies to improve patients' health.

Infectious thrombocytopenia: Viral infections have led to antibody-dependent autoimmune diseases such as anemia and thrombocytopenia in both animal and human models. One of them is the Lactate dehydrogenase elevating virus (LDV), which was used to induce thrombocytopenia in mice (56). This thrombocytopenic model is related to the activation of phagocytic cells by interferon gamma (57). In the

study of Aslam et al., the expression of Toll-like receptors on mice platelets modified the thrombocytopenia induced by lipopolysaccharide (58). Moreover, Endotoxin and Thioflavin were used to induce infection and thrombocytopenia in rats and mice (59, 60). In an in vitro study, lipopolysaccharide significantly increased the enzyme-linked phagocytosis of antibody-coated platelets by human monocytes (61).

Thrombocytopenia in NZW x BXSB: One of the first animal models of immune thrombocytopenia was caused by systemic lupus erythematosus (SLE), which was induced in male NZW x BXSB (W/BF1) mice (62). The mating between female NZW mouse and male BXSB mouse resulted in the birth of male mice (F1) with systematic autoimmune conditions with progressive thrombocytopenia (63).

The parent mice (NZW and BXSB) and the three-month-old female mouse (W/BF1) have normal platelet count (62). Bone marrow transplantation or stem cell transplantation from W/BF1 mouse to the mouse with resistance to autoimmune disease induces thrombocytopenia and lupus nephritis in the recipient animal (63).

Thrombocytopenia caused by platelet injections

Fetal and neonatal immune thrombocytopenia:

Chen et al. developed the fetal and neonatal immune thrombocytopenia model (FNIT) in which the platelets of the mice with integrin $\beta 3+$ ($\beta 3^{+/+}$ FcRn $^{-/-}$ and $\beta 3^{+/+}$ FcRn $^{+/+}$) were transmitted to mice lacking this protein ($\beta 3^{-/-}$ FcRn $^{-/-}$ and $\beta 3^{-/-}$ FcRn $^{+/+}$) and immunized them. Antibodies produced against $\beta 3$ resulted in the formation of thrombocytopenia in adult mice $\beta 3^{+/+}$ FcRn $^{-/-}$. FNIT was observed when $\beta 3^{-/-}$ FcRn $^{+/+}$ female immunized mice were fertilized by $\beta 3^{+/+}$ FcRn $^{+/+}$ male mice. However, it was not observed when $\beta 3^{-/-}$ FcRn $^{-/-}$ female immunized mice were fertilized by $\beta 3^{+/+}$ FcRn $^{-/-}$ male mice (64).

CBA/Ht model: This is a model for inducing thrombocytopenia in mice that results in transient thrombocytopenia in mice through the transfer of rat platelets to CBA/Ht mice (65). Three weeks after transfer of platelet from rats, significant thrombocytopenia was observed in the mice. BALB/C, DBA/2 and C57BL/6 mice were also examined, but no thrombocytopenia is induced after transfer of platelet from rats (45).

Table 1. Summary of non-immune thrombocytopenia animal models and their results

Author	Platelet count	Injection method	Frequency of injection	Dose mg/kg	Animal model	Drug
Hong et al. 2009 (9)	On day 7, 30% decrease	SC	Three consecutive days	100	Mouce Balb/c	
	On day 7, 18% decrease	SC	Three consecutive days	120		
	On day 7, 21% decrease	SC	Three consecutive days	140		
	On day 15, 60% mortality	Tail vein injection	Day 1	200		
	On day 7, 59% decrease		Day 2 – 7	30		
	On day 15, 74%	IP				
Merwid-Lqd et al. 2011 (10)	On day 7, 33% decrease	SC	Three consecutive days	150	Rat	Cyclophosphamide
	On day 11, 75% decrease					
Patil et al. 2013 (11)	Platelet count decreased to $396 \times 10^9/L$	Intragastric	10 Days	15	Rat	
Akhter et al. 2014 (12)	Thrombocytopenia on day 7 (167 and 555 cell/mm^3)	SC	Three consecutive days	50	Rat	
Chang et al. 2009 (13)	Thrombocytopenia on day 7 ($2.68 \times 10^5 /\mu L$)	SC	Three consecutive days	100	Rat	
Zhang et al. 2003 (14)	--	IP	Three consecutive days	30	Rat	
		Tail vein injection	Day 1	200	Mouse Balb/c	
		IP	Day 2 – 8	30		
Kristiana et al. 2013 (15)	49% decrease					
	Thrombocytopenia on day 7 ($176.6 \times 10^3 /\mu L$)	SC	Three consecutive days	25	Rat	
	Thrombocytopenia on day 7	SC	Three	50		

	(111.2 × 10 ³ /μL)		consecutive days			
	Thrombocytopenia on day 7	SC	Three consecutive days	100		
	(34 × 10 ³ /μL)					
	Thrombocytopenia on day 7	SC	Three consecutive days	150		
	(46 × 10 ³ /μL)					
Rinehar et al. 1995 (16)	Thrombocytopenia on days 3 – 10 (Highest decrease on day 10)	Tail vein injection	Single dose	200	Mouse C3H/HeJ	
Tahir et al. 2014 (17)	Thrombocytopenia on day 7 (46 × 10 ⁹ /μL)	IP	Single dose	125	Syrian Mouse	
Ulich et al. 1995 (18)	Thrombocytopenia on days 5 – 8 Recovery on days 15 – 17	IP	Single dose	125	Mouse Balb/c	
Konishi et al. 1995 (19)	60% decrease	IP	Single dose Single dose	1.2 5 Gy/fraction	Mouse ICR	
Bailey et al. 2003 (20)	75 to 180 thousand in most of the studied dogs	IV	Single dose	175	Dog	
Saitoh et al. 2001 (21)	On day 8, the highest decrease	IP	Two consecutive days	50	Syrian Mouse	Carboplatin
Woo et al. 2007 (22)	On days 9 to 11, 90% decrease	IV	Single dose	60	Rat	
McElroy et al. 2013 (23)	Thrombocytopenia on days 7 – 14	IP	Single dose Single dose	62.5 5 Gy/fraction	Mouse B6D2F1 (BDF1)	
McElroy et al. 2013 (23)	Thrombocytopenia on days 35 – 42	IP	Single dose Single dose	56.25 4.5 Gy/fraction	Mouse B6D2F1 (BDF1)	
Hahn et al. 1997 (24)	Significant platelet loss at doses of 200 and 250 (On day 14, 96.500/Lμ).	IV	Single dose Single dose Single dose	150 200 250 mg/m ²	Cat	
Bartucci et al. 2011 (25)	Thrombocytopenia on day 7	IP	Days 0 and 4	5	Mouse C57/BL6	
Asna et al. 2005 (26)	75% decrease	IP	Five consecutive days	5	Mouse ICR	Cisplatin
Hahn et al. 1997 (27)	Platelet count after 5 weeks (308 × 10 ³ /μL)	IV	One day a week for 5 weeks 4 days a week	20 mg/m ² 2 Gy/fraction	Dog	
Knapp et al. 2013 (28)	Bone marrow suppression in 60% of dogs	IV Oral	21 days One day a week	60 mg/m ² 5	Dog	Cisplatin Firocoxib
	Bone marrow suppression in 40% of dogs	IV	21 days	60 mg/m ²	Dog	Cisplatin
Kuter et al. 1995 (29)	Thrombocytopenia on day 14 (11696/μL)	SC	Days 0 and 3	25	Rabbit	
Nasiri et al. 2012 (30)	Thrombocytopenia on day 7 (50 – 70 × 10 ³ /μL)	SC	Days 0, 2, 4, 6	15	Rabbit	
Taguchi et al. 2015 (31)	Thrombocytopenia on day 10 (27.7 × 10 ⁴ /μL)	IP	Days 0 and 3	20	Rat	Busulfan
Inagaki et al. 2004 (32)	Platelet count on days 15 – 18 (less than 200000/μL)	IP	Days 0 and 3	15	Mouse Balb/c	
Pitchford et al. 2005 (33)	83% decrease	IP	Days 0, 2, 4	20	Mouse C57BL/6	
Murai et al. 2014 (34)	Thrombocytopenia on day 4	Tail vein injection	Single dose	2.5	Mouse ddY	Bortezomib
Giver et al.	Thrombocytopenia on day 4	—	Single dose	1	Syrian Mouse	Bortezomib

2012 (35)	(Plate count, $250 \times 10^3/\mu\text{L}$)			2		Romidepsin
Gammulle et al. 2012 (36)	Thrombocytopenia, 24 hours after injection	Oral	Single dose	15	Rat	Hydroxyurea
Lane et al. 2001 (37)	Platelet count on day 7, declining to 40% normal	IP	Single dose	100 $\mu\text{g/day}$	Mouse BALB/c	Anagrelide
Arollado et al. 2013 (38)	Thrombocytopenia on day 15	Oral	15 days	0.083	Rat	
Bano et al. 2013 (39)	Thrombocytopenia, 8 days after the last injection ($287 \times 10^9/\mu\text{L}$)	IP	Two days a week (8 weeks)	0.8	Rat	Oxaliplatin




Figure 1. Summary of various animal models of thrombocytopenia. A. Passive immune thrombocytopenia is caused by the transfer of monoclonal antibodies or serum or transient cell transduction. B. Secondary immune thrombocytopenia is associated with certain diseases and some drugs and infections. C. In the platelet-induced thrombocytopenia model, the GPIIIa female knockout mice were immunized by wild-type platelets plus GPIIIa. Then, they mated with wild-type male mice, and as a result, fetuses with GPIIIa showed significant thrombocytopenia. The transfer of platelets from rats to CBA/Ht mice resulted in transient thrombocytopenia in these mice. Another variant of this model is observed in the fatal and embryonic immune thrombocytopenia in which $\beta 3^{-/-} \text{FcRn}^{+/+}$ mice are immunized by $\beta 3^{+/+} \text{FcRn}^{-/-}$ mouse platelets and after being fertilized by $\beta 3^{+/+} \text{FcRn}^{+/+}$ mice, fetal and neonatal immune thrombocytopenia (FNIT) is observed. D. Non – immune thrombocytopenia is caused by the injection of chemotherapy drugs or simultaneous use of radiation and chemotherapy drugs.

Discussion

The study of human thrombocytopenia is associated with ethical constraints and numerous problems. In addition, in vitro models of cell culture are few and inefficient. For this reason, particular attention has been paid to animal models. There are several empirical models for the development of thrombocytopenia and the identification of the effect of its causative factors, each of which has advantages and disadvantages. The proposed immune and non-immune thrombocytopenia models have advantages and limitations and are selected for therapeutic purposes. In non-immune models, chemotherapy drugs are often used to suppress bone marrow and reduce platelet production, and experimental animals used are often rats and mice.

Cyclophosphamide and carboplatin drugs are most commonly used and inducing thrombocytopenia using these drugs is more efficient. Most animal models of immune thrombocytopenia have been performed on mice. Among the immune models, passive thrombocytopenia and the transfer of antiplatelet

antibodies have been used more frequently. Fewer capabilities of antiserums (serum containing antiplatelet antibodies) with polyclonal antibodies against monoclonal antibodies to produce thrombocytopenia is due to their lower specificity in binding to platelet antigens. Although there are numerous empirical models for animal thrombocytopenia, because of the importance of the subject, the development of research in this field and the identification of more effective models are necessary.

Conflict of Interest: No conflicts of interest.

Acknowledgment

This article is the result of a master's thesis (research project No. 95135) of Kermanshah University of Medical Sciences and hereby, we would like to thank the Deputy of Research and Technology for their financial support.

References

1. Tamamyan G, Danielyan S, Lambert MP. Chemotherapy induced thrombocytopenia in pediatric oncology. *Crit Rev Oncol Hematol*. 2016;99:299-307.
2. Cossu A, Musu M, Mura P, De Giudici L, Finco G. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. *Eur J Clin Pharmacol*. 2014 Jan;70(1):23-8.
3. Hirano A, Ueoka H. Successful treatment of idiopathic thrombocytopenic purpura by Chinese herbal medicine EK-49 and ascorbic acid in an elderly patient developing chronic subdural hematoma. *Geriatr Gerontol Int*. 2007;7(1):83-8.
4. McElroy PL, Wei P, Buck K, Sinclair AM, Eschenberg M, Sasu B, et al. Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia. *Exp Hematol*. 2015;43(6):479-87.
5. Izak M, Bussel JB. Management of thrombocytopenia. *F1000prime reports*. 2014;6.
6. Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIb/IIIa versus GPIIb/IIIa antibodies. *Blood*. 2006;108(3):943-6.
7. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. *Transfus Med Rev*. 2013;27(3):137-45.
8. Minev B. Cancer management in man: chemotherapy, biological therapy, hyperthermia and supporting measures: Springer Science & Business Media; 2011.
9. Hong N, Kong-yan L, Xiao-qi Z, Xue-ying F, Dua-rong Y, Yu-si W. Establishment of a mouse thrombocytopenia model induced by cyclophosphamide. *Zoological Res*. 2009;30(6):645-52.
10. Merwid-Lad A, Trocha M, Chlebda E, Sozański T, Magdalan J, Książczyńska D, et al. The Effects of Morin, a Naturally Occurring Flavonoid, on Cyclophosphamide-Induced Toxicity in Rats. *Adv Clin Exp Med*. 2011;20(6):683-90.
11. Patil S, Shetty S, Bhide R, Narayanan S. Evaluation of platelet augmentation activity of Carica papaya leaf aqueous extract in rats. *J Pharmacog Phytochemist*. 2013;5(1).
12. Akhter T, Khan MI, Eva EO. Comparative evaluation of platelet augmentation activity of Carica papaya leaf juice and hydrocortisone in thrombocytopenic rats. *Banglad J Physiol Pharmacol*. 2015;30(2):32-40.
13. Chang MS, Kim DR, Ko EB, Choi BJ, Park SY, Kang SA, et al. Treatment with Astragali radix and Angelicae radix enhances erythropoietin gene expression in the cyclophosphamide-induced anemic rat. *J Med Food*. 2009;12(3):637-42.
14. Zhang Q, Peng H, Yu X, Xu P. Establishment of a mouse model of cyclophosphamide-induced thrombocytopenia and determination of platelet function in this model. *Acad J First Med College PLA*. 2003;23(12):1277-9, 82.
15. Kristiana H, Nailufar F, Winoto IL, Tjandrawinata RR. A model of rat thrombocytopenia induced by cyclophosphamide. *J Farmasi Indonesia*. 2013;6(3):177-83.
16. Rinehart J, Keville L, Measel J, Spiekerman AM, Burke K. Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. *Blood*. 1995;86(12):4493-9.
17. Tahir N, Zaheer Z, Kausar S, Chiragh S. Prevention of fall in platelet count by carica papaya leaf juice in carboplatin induced thrombocytopenia in mice. *Biomedica*. 2014;30(1):21-5.
18. Ulich TR, del Castillo J, Yin S, Swift S, Padilla D, Senaldi G, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. *Blood*. 1995;86(3):971-6.
19. Konishi H, Ochiya T, Sakamoto H, Tsukamoto M, Saito I, Muto T, et al. Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene. *J Clin Invest*. 1995;96(2):1125-30.
20. Bailey D, Erb H, Williams L, Ruslander D, Hauck M. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. *J Veterin Int Med*. 2003;17(2):199-205.
21. Saitoh M, Taguchi K, Momose K, Suga K, Yamazaki N, Ono C, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. *Cancer Chemother Pharmacol*. 2002;49(2):161-6.
22. Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. *Cancer Chemother Pharmacol*. 2008;62(1):123-33.
23. McElroy PL, Buck K, Eschenberg M, Sasu BJ, Molineux G. Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia. *AACR*. 2013;73(8).

- 24.Hahn KA, McEntee MF, Daniel GB, Legendre AM, Nolan ML. Hematologic and systemic toxicoses associated with carboplatin administration in cats. *Am J Veter Res.* 1997;58(6):677-9.
- 25.Bartucci M, Dattilo R, Martinetti D, Todaro M, Zapparelli G, Di Virgilio A, et al. Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. *Clin Cancer Res.* 2011;17(19):6185-91.
- 26.Asna N, Lewy H, Ashkenazi I, Deutsch V, Peretz H, Inbar M, et al. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. *Life Sci.* 2005;76(16):1825-34.
- 27.Hahn KA, Frazier DL, Nolan ML, Rohrbach BW, Legendre AM. Hematologic Changes Associated With Weekly Low-Dose Cisplatin Administration in Dogs. *Veterin Clin Pathol.* 1997;26(1):29-31.
- 28.Knapp D, Henry C, Widmer W, Tan K, Moore G, Ramos-Vara J, et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. *J Vet Intern Med.* 2013;27(1):126-33.
- 29.Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. *Blood.* 1995;85(10):2720-30.
- 30.Nasiri S, Heidari M, Rivandi S. Infusible platelet membranes improve hemostasis in thrombocytopenic rabbits: studies with two different injection doses. *International Journal of Pharma Sci Res.* 2012;3(12):4895.
- 31.Taguchi K, Ujihira H, Watanabe H, Fujiyama A, Doi M, Takeoka S, et al. Pharmacokinetic study of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ -chain dodecapeptide as a synthetic platelet substitute in an anticancer drug-induced thrombocytopenia rat model. *J Pharm Sci.* 2013;102(10):3852-9.
- 32.Zunjar V, Dash RP, Jivrajani M, Trivedi B, Nivsarkar M. Antithrombocytopenic activity of carpaine and alkaloidal extract of *Carica papaya* Linn. leaves in busulfan induced thrombocytopenic Wistar rats. *J Ethnopharmacol.* 2016;181:20-5.
- 33.Pitchford SC, Momi S, Giannini S, Casali L, Spina D, Page CP, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. *Blood.* 2005;105(5):2074-81.
- 34.Murai K, Kowata S, Shimoyama T, Yashima-Abo A, Fujishima Y, Ito S, et al. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. *Eur J Haematol.* 2014;93(4):290-6.
- 35.Giver CR, Jaye DL, Waller EK, Lonial S. Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib+ romidepsin. *Experiment Hematol.* 2012;40(2):95-6.
- 36..^{*}Gammulle A, Ratnasooriya W, Jayakody J, Fernando C, Kanatiwela C, Udagama PV. Thrombocytosis and anti-inflammatory properties and toxicological evaluation of *Carica papaya* mature leaf concentrate in a murine model. *Int J Med Plant Res.* 2012;1(2):21-30.
- 37.Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, et al. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. *Experiment Hematol.* 2001;29(12):1417-24.
- 38.Arollado EC. Platelet augmentation activity of selected Philippine plants. *Int J Pharma Phytopharmacol Res.* 2013;3(2):121-3.
- 39.Bano N. Sinusoidal dilatations and splenomegaly as feature specifications of drug induced thrombocytopenia in oxaliplatin treated Wistar rats. *Asia J Pharma Clin Res.* 2013;6(2):262-4.
- 40.Lin X, Yin L, Gao R, Liu Q, Xu W, Jiang X, et al. The effects of panaxadiol saponins on megakaryocytic maturation and immune function in a mouse model of immune thrombocytopenia. *Exp Hematol.* 2015;43(5):364-73.
- 41.Hosono M, Sone N, Endo K, Saga T, Kobayashi H, Hosono MN, et al. Kinetics of platelets in dogs with thrombocytopenia induced by antiglycoprotein IIb/IIIa receptor monoclonal antibody. *Nuclear medicine and biology.* 1995;22(1):71-6.
- 42.Corash L, Levin J. The relationship between megakaryocyte ploidy and platelet volume in normal and thrombocytopenic C3H mice. *Experiment Hematol.* 1990;18(9):985-9.
- 43.Cox LH, Downs T, Dagg K, Henthorn J, Burstein S. Interleukin-6 mRNA and protein increase in vivo following induction of acute thrombocytopenia in mice. *Blood.* 1991;77(2):286-93.
- 44.Lecut C, Feeney L, Kingsbury G, Hopkins J, Lanza F, Gachet C, et al. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. *J Thromb Haemos.* 2003;1(12):2653-62.
- 45.Musaji A, Vanhoorelbeke K, Deckmyn H, Coutelier J-P. New model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets. *Exp Hematol.* 2004;32(1):87-94.
- 46.Takada K, Saito M, Kaneko H, Iizuka K, Kokai Y, Fujimoto J. Novel monoclonal antibody reactive with thrombin-sensitive 74-kDa glycoproteins present on platelets and megakaryocytes both from mouse and rat. *Hybridoma.* 1995;14(4):361-7.

47. Sato N, Kiyokawa N, Takada K, Itagaki M, Saito M, Sekino T, et al. Characterization of monoclonal antibodies against mouse and rat platelet glycoprotein V (CD42d). *Hybridoma*. 2000;19(6):455-61.
48. Dekel B, Marcus H, Shenkman B, Shimoni A, Canaan A, Berrebi A, et al. Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies. *Immunology*. 1998;94(3):410-6.
49. Guo L, Yang L, Speck ER, Aslam R, Kim M, McKenzie CG, et al. Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. *Blood*. 2014;123(3):422-7.
50. Chow L, Aslam R, Speck ER, Kim M, Cridland N, Webster ML, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8⁺ T cell-mediated responses that are differentially sensitive to therapy. *Blood*. 2010;115(6):1247-53.
51. Jacobs G, Calvert C, Kaufman A. Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants. *J Am Vet Med Assoc*. 1998;212(5):681-4.
52. Khoutorsky A, Bruchim Y. Transient leucopenia, thrombocytopenia and anaemia associated with severe acute phenobarbital intoxication in a dog. *J Small Animal Prac*. 2008;49(7):67-9.
53. Reilly MP, Sinha U, Andre P, Taylor SM, Pak Y, DeGuzman FR, et al. PRT060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia in a transgenic mouse model. *Am Soc Hematol. Blood*. 2011;117(7):2241-6.
54. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. *Blood*. 2008;112(7):2607-16.
55. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA. *Blood*. 2001;98(8):2442-7.
56. Musaji A, Meite M, Detalle L, Franquin S, Cormont F, Pr  at V, et al. Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. *Autoimmuni Rev*. 2005;4(4):247-52.
57. Musaji A, Cormont F, Thirion G, Cambiaso CL, Coutelier J-P. Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. *Blood*. 2004;104(7):2102-6.
58. Aslam R, Speck ER, Kim M, Crow AR, Bang KA, Nestel FP, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. *Blood*. 2006;107(2):637-41.
59. Sheu J-R, Hung W-C, Wu C-H, Ma M-C, Kan Y-C, Lin C-H, et al. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. *Circulat*. 1999;99(23):3056-62.
60. Yin H, Stojanovic-Terpo A, Xu W, Corken A, Zakharov A, Qian F, et al. Role for Platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality significance. *Arterioscler, Thromb, Vasc Biol*. 2013;33(11):2529-37.
61. Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. *Blood*. 2007;109(11):4803-5.
62. Mizutani H, Furubayashi T, Kuriu A, Take H, Tomiyama Y, Yoshida H, et al. Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet transfer experiments between (NZW x BXSb) F1 and normal mice. *Blood*. 1990;75(9):1809-12.
63. Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSb) F1 mice. *Blood*. 1993;82(3):837-44.
64. Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. *Blood*. 2010;116(18):3660-8.
65. Detalle L, Saxena A, Haddou NO, Uyttenhove C, Van Snick J, Coutelier J-P. Characterization of the T-lymphocyte response elicited by mouse immunization with rat platelets. *Exp Hematol*. 2011;39(6):676-85.